Please login to the form below
Onpattro
This page shows the latest Onpattro news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Ionis sign $3.6bn deal for eplontersen
However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).
Latest news
-
Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn
Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018. ... Onpattro is also currently being evaluated in a phase 3 study in ATTR amyloidosis with cardiomyopathy, with
-
Alnylam scores EU approval for RNAi drug Givlaari
Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar pricing strategy. ... Onpattro, on the other hand, launched with a $450, 000 per year price tag, and subsequently dropped to $345, 000
-
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
-
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease
If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for polyneuropathy in rare disease hereditary ATTR amyloidosis, which was cleared by the FDA in 2018, and Givlaari
-
FDA clears Alnylam’s second RNAi drug for rare disease
Alnylam was also responsible for the first – Onpattro (patisiran) – which was launched for rare disease hereditary ATTR amyloidosis last year with a $450, 000 per year price tag, dropping to $345, ... Alnylam has introduced value-based agreements
More from news
Approximately 7 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Onpattro was approved to treat adults with the. destruction of nerves that results from a rare disease, hereditary transthyretin- mediated (hATTR) amyloidosis, and was launched with a $450, 000 per year ... The company has tried to be creative with its
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Alnylam's Theresa Heggie. Alnylam and its extraordinary ‘gene silencing’ technology is making its debut in Europe with the launch of Onpattro. ... PME talks to its European leader Theresa Heggie. Even as it launches its first ever product Onpattro,
More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
